Luke H. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luke H. Johnson has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dat Thinh Ha
Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - John Strickley
Univ Louisville, Div Dermatol, Louisville, KY USA
2 shared publications - Joongho Joh
Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
2 shared publications - Shadmehr Demehri
Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2 shared publications - Gregory Shoemaker
Department of Medicine, University of Louisville School of Medicine, KY 40202, USA
1 shared publication - Heehwa G. Son
Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk 37673, South Korea
1 shared publication
Latest Publications
- Open Access
- 29 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (2) , 100163
Compromised T Cell Immunity Links Increased Cutaneous Papillomavirus Activity to Squamous Cell Carcinoma Risk
- 29 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (2) , 100163
Open AccessCompromised T Cell Immunity Links Increased Cutaneous Papillomavirus Activity to Squamous Cell Carcinoma Risk
- Open Access
- 26 September 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-6
Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( ) with 100% specificity as a predictive test.
- 26 September 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-6
Open AccessTrending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( ) with 100% specificity as a predictive test.